22 May 2013
Keywords: pfizer, celebrex, found, cd, risks, company, halts
Article | 10 January 2005
As a result of new data showing that its best selling COX-2 inhibitor Celebrex (celecoxib), in high doses, demonstrated an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 January 2005
© 2013 thepharmaletter.com